177 related articles for article (PubMed ID: 18288595)
1. Metformin: effects on micro and macrovascular complications in type 2 diabetes.
Bailey CJ
Cardiovasc Drugs Ther; 2008 Jun; 22(3):215-24. PubMed ID: 18288595
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus.
Otsuki M; Goya K; Kasayama S
Vasc Health Risk Manag; 2005; 1(3):209-15. PubMed ID: 17319106
[TBL] [Abstract][Full Text] [Related]
3. Metformin therapy and clinical uses.
Scarpello JH; Howlett HC
Diab Vasc Dis Res; 2008 Sep; 5(3):157-67. PubMed ID: 18777488
[TBL] [Abstract][Full Text] [Related]
4. [Primary preventive effect of metformin upon atherosclerosis in patients with type 2 diabetes mellitus].
Zhang XY; Du JL; Jia YJ; Bai R; Yang Y; Ba Y; Xing Q; Men LL
Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(30):2134-7. PubMed ID: 20058619
[TBL] [Abstract][Full Text] [Related]
5. Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes--a randomized controlled trial.
Esposito K; Maiorino MI; Di Palo C; Gicchino M; Petrizzo M; Bellastella G; Saccomanno F; Giugliano D
Diabetes Obes Metab; 2011 May; 13(5):439-45. PubMed ID: 21255215
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of metformin against insulin resistance parameters: sinking the iceberg.
Zimmet P; Collier G
Drugs; 1999; 58 Suppl 1():21-8; discussion 75-82. PubMed ID: 10576521
[TBL] [Abstract][Full Text] [Related]
7. Do effects on blood pressure contribute to improved clinical outcomes with metformin?
Schäfers RF
Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S62-70. PubMed ID: 14502102
[TBL] [Abstract][Full Text] [Related]
8. Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients.
Mary A; Hartemann A; Liabeuf S; Aubert CE; Kemel S; Salem JE; Cluzel P; Lenglet A; Massy ZA; Lalau JD; Mentaverri R; Bourron O; Kamel S
Cardiovasc Diabetol; 2017 Feb; 16(1):24. PubMed ID: 28202017
[TBL] [Abstract][Full Text] [Related]
9. Metformin: diamonds are forever.
Papanas N; Maltezos E; Mikhailidis DP
Expert Opin Pharmacother; 2009 Oct; 10(15):2395-7. PubMed ID: 19678795
[TBL] [Abstract][Full Text] [Related]
10. Impact of Metformin on Exercise-Induced Metabolic Adaptations to Lower Type 2 Diabetes Risk.
Malin SK; Braun B
Exerc Sport Sci Rev; 2016 Jan; 44(1):4-11. PubMed ID: 26583801
[TBL] [Abstract][Full Text] [Related]
11. Metformin delays the manifestation of diabetes and vascular dysfunction in Goto-Kakizaki rats by reduction of mitochondrial oxidative stress.
Rösen P; Wiernsperger NF
Diabetes Metab Res Rev; 2006; 22(4):323-30. PubMed ID: 16444763
[TBL] [Abstract][Full Text] [Related]
12. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
Hemmingsen B; Lund SS; Vaag A
Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
[TBL] [Abstract][Full Text] [Related]
13. Effects of oral antihyperglycemic agents in modifying macrovascular risk factors in type 2 diabetes.
Lebovitz HE
Diabetes Care; 1999 Apr; 22 Suppl 3():C41-4. PubMed ID: 10189561
[TBL] [Abstract][Full Text] [Related]
14. [United Kingdom Prospective Diabetes Study (UKPDS): 10 years later].
Scheen AJ; Paquot N; Lefebvre PJ
Rev Med Liege; 2008 Oct; 63(10):624-9. PubMed ID: 19009971
[TBL] [Abstract][Full Text] [Related]
15. Antidiabetic agents and endothelial dysfunction - beyond glucose control.
Eriksson L; Nyström T
Basic Clin Pharmacol Toxicol; 2015 Jul; 117(1):15-25. PubMed ID: 25827165
[TBL] [Abstract][Full Text] [Related]
16. Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects.
Prescrire Int; 2014 Nov; 23(154):269-72. PubMed ID: 25954799
[TBL] [Abstract][Full Text] [Related]
17. The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients.
Ersoy C; Kiyici S; Budak F; Oral B; Guclu M; Duran C; Selimoglu H; Erturk E; Tuncel E; Imamoglu S
Diabetes Res Clin Pract; 2008 Jul; 81(1):56-60. PubMed ID: 18358555
[TBL] [Abstract][Full Text] [Related]
18. Impact of 6 weeks of treatment with low-dose metformin and atorvastatin on glucose-induced changes of endothelial function in adults with newly diagnosed type 2 diabetes mellitus: A single-blind study.
Tousoulis D; Koniari K; Antoniades C; Miliou A; Noutsou M; Nikolopoulou A; Papageorgiou N; Marinou K; Stefanadi E; Stefanadis C
Clin Ther; 2010 Sep; 32(10):1720-8. PubMed ID: 21194594
[TBL] [Abstract][Full Text] [Related]
19. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
[TBL] [Abstract][Full Text] [Related]
20. Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance.
de Aguiar LG; Bahia LR; Villela N; Laflor C; Sicuro F; Wiernsperger N; Bottino D; Bouskela E
Diabetes Care; 2006 May; 29(5):1083-9. PubMed ID: 16644641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
